Rules

Rules Table

Pharmacist-authored demo content. Not clinical guidance.
Last reviewed: 10/04/2026

How to read this

The AI matches what the patient says against the trigger phrases in each rule. When a rule matches, the pharmacist sees the recommendation and the name of the rule that triggered it. The pharmacist decides what to say and whether an event meets seriousness criteria. The tool only prompts.

Seriousness criteria

In order to maintain scope of project and reflect common practice if it is a not a serious event it will be categorized as mild

A report is serious when the patient outcome is one of (FDA MedWatch definition):

• Death
• Life-threatening
• Hospitalization (initial or prolonged)
• Disability or permanent damage
• Congenital anomaly / birth defect
• Required intervention to prevent permanent impairment or damage
• Other serious (important medical event)

Source: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event

---

Note: to remain in scope and timeline constraint we will only construct rules for selected indications, adults 18+, speaking directly to patient, and if multiple loading doses available based on weight or other criteria one treatment regimen will be selected

Drug 1: Dupixent

Indication(s): Atopic Dermatitis (AD)
Product Information: Patient will receive 1 box that includes 2 pens, each pen is 300 mg/2 mL
Route / frequency: Initial loading dose: 2 Pens for a total of 600 mg, then Maintenance dosing: 1 Pen for a total of 300 mg every 2 weeks starting on day 15

ADE rules

Rule ID	Patient might say (trigger phrases)	Standardized label	Seriousness prompts (what to ask)	Recommendation to show the pharmacist	Escalate when	Source
D1-01	[ ]	[ ]	[e.g. ER visit? admitted? interfering with daily life?]	[ ]	[ ]	[label section / reference]
D1-02	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]
D1-03	[ ]	[ ]	[ ]	[ ]	[ ]	[ ]

Missed-dose rule

Rule ID	Situation	Recommendation to show the pharmacist	Source
D1-MD	[Patient says they missed a dose]	[ ]	[ ]

Red-flag combinations

Rule ID	Combination	Recommendation	Source
D1-RF	[e.g. symptom A together with symptom B]	[ ]	[ ]

Call steps (all drugs, every check-in)

Step	Key points	Source
Self-identify	State your name, title, and where you're calling from	Standard practice (demo)
Recording disclosure	Tell the patient the call is being recorded	Standard practice (demo)
Verify patient identity	Confirm the patient's date of birth before discussing any PHI	Standard practice (demo)
Manufacturer reporting and consent	Explain that side effects and product complaints are reported to the manufacturer, and ask whether they may contact the patient, the doctor, both, or neither if they have follow up questions	Standard practice (demo)
Closing reminder	Tell the doctor about any side effects; call 911 for a serious emergency	Standard practice (demo)

Dupixent counseling topics (Indication: Asthma)

Topic	When it applies	Key points to cover	Source
How it works	New start, or if asked	Blocks signals from two proteins (IL-4 and IL-13) that drive airway inflammation; helps reduce asthma attacks and improve breathing	Label
Common side effects	Every check-in	Injection site reactions, throat pain, a high eosinophil count on blood tests, and parasitic infections	Label (asthma)
Serious side effects	New start, or if asked	Allergic reactions (trouble breathing, swelling of the face, lips, tongue, or throat, fainting, hives, rash); new or worsening eye problems; joint pain that limits walking; signs of blood vessel inflammation (rash, chest pain, worse shortness of breath, numbness or tingling)	Label
Storage	New start, or if asked	Keep refrigerated in the original carton; if needed, room temperature up to 25°C (77°F) for at most 14 days, then use or discard; protect from heat and sunlight	Label
Before injecting	New start, or if asked	Let it reach room temperature with the cap on (about 45 minutes for the 300 mg/2 mL; about 30 minutes for the 200 mg/1.14 mL)	Label
Injection technique	New start, or if asked	Thigh or abdomen, staying 2 inches from the navel; upper arm only if someone else gives it	Label / IFU
Missed dose, every other week	New start, if asked, and every check-in	Inject within 7 days of the missed dose and continue the original schedule; if more than 7 days, wait for the next scheduled dose	Manufacturer patient FAQ

---

Drug 2: Jascayd

(same structure)

Drug 3: Tymlos

(same structure)

---

EXAMPLE ROW (format only; delete before publishing)

Rule ID	Patient might say	Standardized label	Seriousness prompts	Recommendation	Escalate when	Source
EX-01	"diarrhea," "loose stools," "stomach upset," "going to the bathroom a lot"	Diarrhea	Any ER visit or admission? Signs of dehydration? How long has it lasted?	Replace fluids; consider an anti-diarrheal if needed; ask about duration and other symptoms	Fever, blood in stool, signs of dehydration, or symptoms that persist or worsen	[check the drug's label]

---

Rules that apply to every drug

Rule	Behavior
Missing detail	If a reported event has no duration or impact on daily life, show a prompt to ask
Seriousness prompts	Always ask about ER visits, hospitalization, and inability to do normal activities; the pharmacist decides whether criteria are met
Patient's own attribution	If the patient blames something else (food poisoning, a new supplement), record it as stated; do not decide causality
Unmatched symptom	If nothing matches, record the verbatim text and show "no rule matched; pharmacist to assess"
Verbatim first	The patient's exact words always stay in the note next to the standardized label